Gluten-free bread promises improved texture, taste

By Catherine Boal

- Last updated on GMT

Related tags Coeliac disease Wheat

Scientists have developed a new variety of gluten-free bread
suitable for consumers suffering from coeliac disease and boasting
a longer shelf-life, increased nutritional value and better texture
than products already available.

Coeliac disease is caused by an intolerance to gluten - the protein found in wheat, rye and barley - and currently affects an average of one in 300 people in Europe and the US. In Germany the figure is higher at one in 200, while the UK reports a figure of one in 100.

Estimates by market researcher Mintel reveal the overall free-from food market in the UK was worth around £90m (€131m) last year, with gluten-/wheat-free products forming the largest sector, accounting for 54 per cent of value sales. It has proved difficult however for manufacturers to remove gluten while still providing a pleasant taste and structure to products.

Now researchers at the Food Technology Plant Special Research Centre (CeRPTA), attached to the Universitat Autonoma de Barcelona, claim to have created a type of bread with a similar taste and consistency to that derived from wheat flour - with a spongy texture and normal volume.

The CeRPTA said in a statement: "The bread has a pleasant taste and texture and is of a high-quality. It was produced with primary materials that are 100 per cent gluten-free, is highly nutritional and can be enjoyed both by coeliacs and by the general population."

In addition, the product is made from plant-based ingredients and suitable for those with an intolerance to lactose and eggs - opening up the possibility for further application in the free-from market.

Related topics Ingredients

Related news

Related products

show more

What consumers are looking for in alcohol drinks

What consumers are looking for in alcohol drinks

Content provided by ADM | 12-Apr-2024 | Application Note

Are you ready to understand the consumer insights driving the future of the alcoholic beverage market? We've assembled a consumer insights report...

Redefine resilience with IMMUSE

Redefine resilience with IMMUSE

Content provided by Kyowa Hakko (US) | 02-Apr-2024 | White Paper

IMMUSETM is a universal postbiotic — the first of its kind to activate pDC cells for year-round immune support.

Related suppliers

Follow us

Products

View more

Webinars